CanSino (Shanghai) Biotechnologies Co., Ltd, Shanghai, People's Republic of China.
CanSino Biologics, Tianjin, People's Republic of China.
Emerg Microbes Infect. 2022 Dec;11(1):1550-1553. doi: 10.1080/22221751.2022.2081616.
In order to overcome the pandemic of COVID-19, messenger RNA (mRNA)-based vaccine has been extensively researched as a rapid and versatile strategy. Herein, we described the immunogenicity of mRNA-based vaccines for Beta and the most recent Omicron variants. The homologous mRNA-Beta and mRNA-Omicron and heterologous Ad5-nCoV plus mRNA vaccine exhibited high-level cross-reactive neutralization for Beta, original, Delta, and Omicron variants. It indicated that the COVID-19 mRNA vaccines have great potential in the clinical use against different SARS-CoV-2 variants.
为了克服 COVID-19 大流行，信使 RNA（mRNA）疫苗作为一种快速且通用的策略得到了广泛研究。在此，我们描述了针对 Beta 和最新的奥密克戎变异株的 mRNA 疫苗的免疫原性。同源的 mRNA-Beta 和 mRNA-Omicron 以及异源的 Ad5-nCoV 加 mRNA 疫苗对 Beta、原始株、Delta 和奥密克戎变异株均表现出高水平的交叉中和反应。这表明 COVID-19 mRNA 疫苗在临床应用于对抗不同的 SARS-CoV-2 变异株方面具有巨大潜力。
Zotero 插件